VRTX

SELL

Vertex Pharmaceuticals Incorpor

Healthcare · Rank #80 · Analyzed Oct 18, 2026

$499.74

Current Price

$252.64

Intrinsic Value

-49.4%

Upside/Downside

4.5/10

Score

4.5/5

Quality

Analysis Summary

Valuation Consensus0/3 methods agree

Quality Score4.5/5.0

Framework RatingSELL

Price vs Intrinsic ValueOvervalued by 49.4%

Fair Value Range

Low$54.14

Base (IV)$252.64

High$291.13

Entry Points

Conservative$37.90

Moderate$54.14

Aggressive$176.85

Quality & Moat Breakdown

Return on Equity23.5% → 1.0/1.0

Debt LevelD/E 10 → 1.0/1.0

Revenue QualityGrowth 7.9%, margin Δ+6.7% → 1.0/1.0

Moat Strength3.0/5 → 0.5/1.0

Profit Margins35.0% → 1.0/1.0

Methodology

This analysis uses a unified valuation framework combining three methods, Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation, with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.